Skip to main content
TipRanks
Go Ultimate75% OFF

Bavarian Nordic (BVNRY) AI Stock Analysis

177 Followers
BVNRY

Bavarian Nordic

(Other OTC:BVNRY)

Select Model
Rating:74Outperform
Price Target:$13.00â–²(11.46% Upside)
Action:reiterated
Date:11/15/26

Overall score is driven mainly by strong financial quality (sustained profitability and very low leverage) and a constructive earnings update with maintained 2026 guidance and strong segment momentum. The score is tempered by recent revenue contraction and weaker/less consistent free-cash-flow trends, plus mixed near-term technical momentum.

Positive Factors
Conservative balance sheetVery low leverage gives Bavarian Nordic substantial financial flexibility to fund product development, manufacturing needs and commercial expansion without relying heavily on debt. The strong equity base also reduces balance-sheet pressure during periods of uneven vaccine demand or investment spending.
Negative Factors
Volatile revenue trajectoryThe sharp change in revenue direction shows that reported growth remains uneven and difficult to forecast. A volatile top line can complicate production planning, resource allocation and investor expectations, even while the company remains profitable and benefits from stronger individual segments.

Bavarian Nordic (BVNRY) vs. SPDR S&P 500 ETF (SPY)

-10%0%10%20%30%40%BVNRY+23.97%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$2.77B
Dividend Yield
―
Average Volume (3M)
2,940
Price to Earnings (P/E)
12.0
Beta (1Y)
0.73
Revenue Growth
-3.78%
EPS Growth
-60.52%
Country
US
Employees
1,795
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Bavarian Nordic Business Overview & Revenue Model

Company Description

Bavarian Nordic A/S is a Danish biopharmaceutical company specializing in the development, production, and global commercialization of essential, life-saving vaccines. Its marketed portfolio includes non-replicating vaccines for smallpox and monkeypo...

How the Company Makes Money

Bavarian Nordic primarily makes money by selling vaccines and related services under a mix of government/public-sector procurement, commercial distribution, and partner-enabled sales depending on product and region. Key revenue streams include: (1) P...

Bavarian Nordic Earnings Call Summary

Earnings Call Date:Nov 13, 2026(Q3-2026)|% Change Since:-1.44%|Next Earnings Date:Mar 11, 2027
Earnings Call SentimentPositive

The call was strongly positive overall. Bavarian Nordic reported robust organic growth, very strong Travel Health and rabies performance, high EBITDA margins, strong cash flow, substantial contract coverage and a maintained 2026 outlook. The principal challenges were TBE supply and shelf-life issues, slower-than-expected U.S. Vimkunya uptake, Q4 seasonality and investment needs to support longer-term rabies capacity. These challenges were presented as manageable within the company's current plans.

Positive Updates

Strong Nine-Month Revenue and Organic Growth
Revenue for the first 9 months was just under DKK 4.9 billion, representing reported growth of 2%. Adjusting for discontinued partnerships and foreign exchange, organic growth was over 9%.

Negative Updates

TBE Shelf-Life and Supply Challenges
The Encepur tick-borne encephalitis business entered the year with relatively low shelf life, making it difficult to sell to wholesalers and distributors. Although shelf life has been increased, the company said it was not fully finished with the work, and the issue caused periods of supply constraints and disruption. TBE showed negative growth in Q3, despite 9% growth on a year-to-date basis.

Company Guidance

For 2026, Bavarian Nordic is maintaining revenue guidance of around DKK 6.1 billion, including approximately DKK 4 billion from Travel Health, while also projecting DKK 3.4 billion from Travel Health and DKK 2.5 billion from Public Preparedness, with an EBITDA margin of around 32%; Public Preparedness is targeting DKK 2.5 billion for the full year versus a normal business base level of DKK 1.5 billion to DKK 2 billion, and Vimkunya has soft guidance of DKK 200 million for the full year. The company expects a lower EBITDA margin in Q4 due to expected lower revenue compared to the previous 9 months and back-end loaded investments into R&D projects and sales and marketing, said it is probably on the conservative side, and expects its manufacturing changes to enable supply into expected demand during '27, although additional investments might be needed beyond '27.

Bavarian Nordic Financial Statement Overview

Summary

Financials are solid overall: profitability has been sustained since 2023 with healthy TTM gross (~50%) and net (~14%) margins, and the balance sheet is conservatively financed with very low leverage (debt-to-equity ~1% in 2023–TTM). Offsetting this strength, revenue has recently contracted (TTM revenue growth about -23%) and free cash flow declined sharply in TTM, indicating volatility in both growth and cash conversion.

Income Statement

72Positive

Balance Sheet

88Very Positive

Cash Flow

67Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue6.06B5.93B5.72B7.06B3.15B1.90B
Gross Profit3.17B2.81B2.82B4.53B1.70B570.32M
EBITDA1.90B1.60B1.67B2.05B84.28M85.94M
Net Income909.39M1.32B987.98M1.48B-347.38M-464.77M
Balance Sheet
Total Assets15.31B14.95B14.41B14.35B12.39B12.09B
Cash, Cash Equivalents and Short-Term Investments3.03B3.33B2.18B1.87B2.85B3.72B
Total Debt124.93M130.86M128.25M145.30M1.76B1.13B
Total Liabilities1.58B2.08B3.00B4.01B5.24B4.71B
Stockholders Equity13.73B12.87B11.41B10.34B7.15B7.37B
Cash Flow
Free Cash Flow843.05M2.42B262.19M141.80M-1.16B-1.42B
Operating Cash Flow1.03B2.62B1.95B1.12B220.05M-358.50M
Investing Cash Flow-1.31B-2.39B-1.87B-945.56M-877.40M-2.88B
Financing Cash Flow-651.59M-109.97M55.77M735.83M635.82M3.54B

Bavarian Nordic Technical Analysis

Technical Analysis SentimentPositive
Last Price11.66

Price Trends

50DMA11.54Positive
100DMA10.62Positive
200DMA10.24Positive

Market Momentum

MACD0.08Positive
RSI44.30Neutral
STOCH2.37Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BVNRY, the sentiment is Positive. The current price of 11.66 is below the 20-day moving average (MA) of 12.22, above the 50-day MA of 11.54, and above the 200-day MA of 10.24, indicating a neutral trend. The MACD of 0.08 indicates Positive momentum. The RSI at 44.30 is Neutral, neither overbought nor oversold. The STOCH value of 2.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BVNRY.

Bavarian Nordic Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

BVNRY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ADMAADMA82Outperform$3.03B17.3242.56%―6.26%-10.51%
BVNRYBVNRY74Outperform$2.77B12.026.86%―-3.78%-60.52%
ABUSABUS70Outperform$626.97M3.62129.13%―1142.57%―
VIRVIR68Neutral$1.71B-7.97-21.38%―1695.96%65.40%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
BCRXBCRX49Neutral$1.96B-5.6494.36%―60.30%-3028.57%
NVAXNVAX43Neutral$1.41B-18.5345.13%―-61.33%-121.87%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%BVNRYBCRXNVAXABUSADMAVIRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
BVNRY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
BVNRYBavarian Nordic A/S11.662.1322.41%
BCRXBioCryst Pharmaceuticals7.610.588.25%
NVAXNovavax8.531.7325.37%
ABUSArbutus Biopharma4.09-0.45-9.91%
ADMAADMA Biologics Inc13.68-1.74-11.28%
VIRVir Biotechnology, Inc.9.964.4781.42%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 15, 2026